KARD peer analysis
Kardigan (KARD) against its competitors: price, today's move, 1-year return and market value side by side.
KARD and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| BRVE Braveheart Bio | $19.46 | 4.62% | – | – |
| CYTK Cytokinetics | $56.22 | 1.96% | -7.50% | $7.75B |
| IKT Inhibikase Therapeutics | $1.68 | 12.00% | 12.00% | $234.42M |
| NAMS NewAmsterdam Pharma | $19.18 | 0.95% | -48.07% | $2.29B |
| RNA Atrium Therapeutics | $8.18 | -2.39% | -88.28% | $139.92M |
| TNYA Tenaya Therapeutics | $0.37 | -5.91% | -70.55% | $85.93M |
| KARD Kardigan | $15.21 | 0.20% | – | – |
- KARD's peers: BRVE (Braveheart Bio), CYTK (Cytokinetics), IKT (Inhibikase Therapeutics), NAMS (NewAmsterdam Pharma), RNA (Atrium Therapeutics), TNYA (Tenaya Therapeutics).
Updated 2026-11-11 00:49 UTC